World Bio Summit: Collaboration, Preparedness Key Words For Next Pandemic
Korea Could Act As Global Bridge
Executive Summary
The recent World Bio Summit in Seoul saw executives of global pharmas including Pfizer, Merck and Moderna discuss strategic approaches to advance the development of, and ensure equitable access to, vaccines, and also highlighted Korea’s potential role in ongoing global efforts.
You may also be interested in...
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.
Emocog Setting The Standard For Cognitive Decline DTx in Korea
In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.
What's Keeping Korea From Adopting Decentralized Clinical Trials?
The current status of decentralized clinical trials in Korea and the country’s efforts to boost activity in this area were discussed at the recent Bio Korea meeting, with cultural and medical practices, along with technological and medical literacy, among the areas seen as affecting broader adoption of the various elements of the approach.